Editas Medicine (LSE:0IFK) - Hisse Senedi Fiyatı, Haberler ve Analizler

0IFK Stoklara Genel Bakış

Klinik aşamada bir genom düzenleme şirketi olan Editas Medicine, Inc. bir dizi ciddi hastalığı tedavi etmek için dönüştürücü genomik ilaçlar geliştirmeye odaklanmaktadır. Daha fazla detay

0IFK temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 14.32% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 0.7% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Son 3 ayda dalgalı hisse senedi fiyatı

Editas Medicine, Inc. Rakipler

Avacta Group

AIM:AVCT

UK£170.1m

Bioventix

AIM:BVXP

UK£195.7m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Arecor Therapeutics

AIM:AREC

UK£28.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Editas Medicine
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.45
52 Haftanın En Yüksek Seviyesi	US$11.66
52 Haftanın En Düşük Seviyesi	US$2.30
Beta	2.01
11 Aylık Değişim	-23.23%
3 Aylık Değişim	-37.85%
1 Yıllık Değişim	-76.74%
33 Yıllık Değişim	-92.38%
5 Yıllık Değişim	-91.65%
Halka arzdan bu yana değişim	-93.19%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0IFK	GB Biotechs	GB Pazar
7D	-7.9%	0.3%	2.2%
1Y	-76.7%	-18.3%	8.0%

Getiri vs. Endüstri: 0IFK geçen yıl % -18.3 oranında getiri sağlayan UK Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0IFK geçen yıl % 8 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0IFK's price volatile compared to industry and market?
0IFK volatility
0IFK Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0IFK hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0IFK 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	265	Gilmore O’Neill	www.editasmedicine.com

Klinik aşamada bir genom düzenleme şirketi olan Editas Medicine, Inc. bir dizi ciddi hastalığı tedavi etmek için dönüştürücü genomik ilaçlar geliştirmeye odaklanmaktadır. CRISPR teknolojisine dayalı tescilli bir gen düzenleme platformu geliştirmektedir. Şirket, Leber Konjenital Amaurosis için Faz 1/2 BRILLIANCE denemesinde olan EDIT-101'i ve orak hücre hastalığı ve transfüzyona bağlı beta-talasemiyi tedavi etmek için klinik geliştirme gen düzenlenmiş bir ilaç olan reni-cel'i geliştirmektedir.

Editas Medicine, Inc. Temel Bilgiler Özeti

Editas Medicine'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0IFK temel i̇stati̇sti̇kler
Piyasa değeri	US$201.42m
Kazançlar(TTM)	-US$210.57m
Gelir(TTM)	US$61.76m

3.3x

P/S Oranı

-1.0x

F/K Oranı

0IFK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0IFK gelir tablosu (TTM)
Gelir	US$61.76m
Gelir Maliyeti	US$220.19m
Brüt Kâr	-US$158.43m
Diğer Giderler	US$52.14m
Kazançlar	-US$210.57m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.55
Brüt Marj	-256.53%
Net Kâr Marjı	-340.96%
Borç/Özkaynak Oranı	0%

0IFK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0IFK Stoklara Genel Bakış

Ödüller

Risk Analizi

Editas Medicine, Inc. Rakipler

AIM:AVCT

UK£170.1m

AIM:BVXP

UK£195.7m

AIM:TRX

UK£40.6m

AIM:AREC

UK£28.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.55 loss in 3Q 2023)

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.55 loss in 3Q 2023)

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

New major risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

Independent Lead Director recently bought US$254k worth of stock

First quarter 2024 earnings released: US$0.76 loss per share (vs US$0.71 loss in 1Q 2023)

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Full year 2023 earnings released: US$2.02 loss per share (vs US$3.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.81 loss in 3Q 2022)

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.78 loss in 2Q 2022)

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Insider recently sold US$62k worth of stock

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.74 loss in 1Q 2022)

Full year 2022 earnings released: US$3.21 loss per share (vs US$2.85 loss in FY 2021)

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2021)

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.81 loss in 2Q 2021)

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.86 loss in 1Q 2021)

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Editas Medicine, Inc. Terminates Lisa Michaels as Chief Medical Officer

Chairman recently sold US$492k worth of stock

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Executive VP & Chief Medical Officer recently sold US$60k worth of stock

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.13 profit in 3Q 2020)

Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 for an Oral Presentation at the XIXth International Symposium on Retinal Degeneration

Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology

Second quarter 2021 earnings released: US$0.81 loss per share (vs US$0.43 loss in 2Q 2020)

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

First quarter 2021 earnings released: US$0.86 loss per share (vs US$0.69 loss in 1Q 2020)